These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16920565)

  • 1. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia.
    Ferrara F; Palmieri S; Pollio F; Lo Pardo C; Graziano D; Celentano M; D'Amico MR; Vicari L; Izzo B; Pane F
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):981-6. PubMed ID: 16920565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
    Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
    Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
    Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
    Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
    Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
    Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia.
    Ferrara F; Viola A; Copia C; Falco C; D'Elia R; Tambaro FP; Correale P; D'Amico MR; Vicari L; Palmieri S
    Hematol Oncol; 2007 Jun; 25(2):84-9. PubMed ID: 17361983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
    Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
    Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
    Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U
    Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
    Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
    Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
    Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
    Cancer; 2007 Mar; 109(6):1152-6. PubMed ID: 17315232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
    Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
    Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
    Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.